NEULS: Risk of Psychopathology and Neurocognitive Impairment in Leukemia Survivors

Category:

Long-term Effects

Eligibility Overview:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

  • Participant was enrolled on SJCRH TOTXV ALL protocol (or Best Clinical Management that followed the same treatment provided in the TOTXV protocol)
  • Minimum of five years post diagnosis of ALL
  • Minimum age of 8.0 years at time of follow-up evaluation

Description

This is a non-therapeutic study that will characterize patterns of long-term neurocognitive outcomes and brain maturation in survivors of childhood leukemia, and will utilize existing data collected during acute treatment to identify predictors of such outcomes. The goal is to identify children treated for childhood acute lymphoblastic leukemia (ALL) that are at the greatest risk for long-term neurocognitive problems (the ability to concentrate, remember things, process information, learn, speak, and understand), behavioral problems (Attention Deficit/Hyperactivity Disorder) and other problems such as depression and anxiety. The association between genetic polymorphisms and the presence of these neurocognitive and behavioral problems will also be explored.

Objectives

  • To evaluate the association between changes in basic cognitive and behavioral functioning by the end of chemotherapy treatment, and the later development of higher order executive functions in pediatric ALL.
  • To evaluate the association between acute treatment-related changes in brain integrity and subsequent brain maturation in long-term survivors of pediatric ALL.
  • To evaluate the association between patterns of behavioral and executive dysfunction and brain maturation in long-term survivors of pediatric ALL.
  • To explore the association between genetic polymorphisms in key enzyme pathways and higher order brain development in long-term survivors of pediatric ALL.
  • To explore associations between biologic and behavioral indices of fatigue/sleep and higher order brain development in long-term survivors of pediatric ALL.

Eligibility

  • Participant was enrolled on SJCRH TOTXV ALL protocol (or Best Clinical Management that followed the same treatment provided in the TOTXV protocol)
  • Minimum of five years post diagnosis of ALL
  • Minimum age of 8.0 years at time of follow-up evaluation

And does not have:

  • History of head injury, neurological condition unrelated to ALL treatment, or diagnosis of a genetic disorder associated with neurocognitive impairment (e.g. Down Syndrome)

Principal Investigator

Kevin Krull, PhD

St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105  USA
Voice: 1-888-226-4343 or 901-595-4055
24-Hour Emergency Access Pager: 1-800-349-4334
Email: referralinfo@stjude.org

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.